Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$290.38 +0.4%	$293.12	$253.30 ▼ $339.17	$156.33B	0.49	2.87 million shs	1.14 million shs
GEVA (GEVA)		$0.00	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$119.05 -0.9%	$111.59	$72.89 ▼ $121.83	$147.71B	0.33	8.35 million shs	4.11 million shs
VRTX Vertex Pharmaceuticals	$390.96 -1.3%	$447.18	$362.50 ▼ $519.88	$100.24B	0.44	1.65 million shs	1.31 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+1.53%	+1.64%	-2.59%	+6.49%	-10.55%
GILD Gilead Sciences	+0.10%	+8.94%	+7.18%	+19.73%	+62.40%
VRTX Vertex Pharmaceuticals	+2.10%	+2.66%	-16.18%	-8.85%	-15.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.6606 of 5 stars	2.2	4.0	3.3	3.9	2.8	2.5	1.9
GEVA (GEVA)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	4.8549 of 5 stars	1.4	5.0	4.2	4.1	2.9	2.5	3.1
VRTX Vertex Pharmaceuticals	4.9136 of 5 stars	4.3	3.0	0.0	3.3	3.2	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.33	Hold	$303.76	4.61% Upside
GEVA (GEVA)	0.00	N/A	N/A	N/A
GILD Gilead Sciences	2.80	Moderate Buy	$114.82	-3.55% Downside
VRTX Vertex Pharmaceuticals	2.56	Moderate Buy	$497.10	27.15% Upside

Current Analyst Ratings Breakdown

Latest GEVA, AMGN, GILD, and VRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$96.00 ➝ $98.00
8/8/2025	GILD Gilead Sciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$108.00 ➝ $112.00
8/8/2025	GILD Gilead Sciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$108.00 ➝ $127.00
8/6/2025	AMGN Amgen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$305.00 ➝ $310.00
8/6/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$330.00 ➝ $333.00
8/6/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$326.00 ➝ $317.00
8/6/2025	VRTX Vertex Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$424.00 ➝ $411.00
8/6/2025	VRTX Vertex Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$558.00 ➝ $546.00
8/6/2025	VRTX Vertex Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$460.00
8/5/2025	VRTX Vertex Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$442.00 ➝ $438.00
8/5/2025	VRTX Vertex Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$520.00 ➝ $490.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.68	$30.96 per share	9.38	$13.80 per share	21.04
GEVA (GEVA)	N/A	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$28.75B	5.14	$6.81 per share	17.47	$15.79 per share	7.54
VRTX Vertex Pharmaceuticals	$11.42B	8.78	N/A	N/A	$66.99 per share	5.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$12.23	23.74	13.58	2.46	18.96%	174.71%	13.12%	10/29/2025 (Estimated)
GEVA (GEVA)	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$480M	$5.02	23.71	14.68	0.75	21.86%	50.99%	17.24%	N/A
VRTX Vertex Pharmaceuticals	-$535.60M	$13.99	27.95	22.33	N/A	31.86%	23.91%	17.14%	N/A

Latest GEVA, AMGN, GILD, and VRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GILD Gilead Sciences	$1.96	$2.01	+$0.05	$1.55	$6.95 billion	$7.08 billion
8/5/2025	Q2 2025	AMGN Amgen	$5.28	$6.02	+$0.74	$2.65	$8.86 billion	$9.18 billion
8/4/2025	Q2 2025	VRTX Vertex Pharmaceuticals	$4.24	$4.52	+$0.28	$3.99	$2.90 billion	$2.94 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.28%	N/A	77.84%	14 Years
GEVA (GEVA)	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.65%	N/A	62.95%	10 Years
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest GEVA, AMGN, GILD, and VRTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/8/2025	GILD Gilead Sciences	quarterly	$0.79	2.7%	9/15/2025	9/15/2025	9/29/2025
8/1/2025	AMGN Amgen	quarterly	$2.38	3.21%	8/22/2025	8/22/2025	9/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	7.24	1.31	0.98
GEVA (GEVA)	N/A	N/A	N/A
GILD Gilead Sciences	1.13	1.32	1.15
VRTX Vertex Pharmaceuticals	N/A	2.52	2.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
GEVA (GEVA)	N/A
GILD Gilead Sciences	83.67%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
GEVA (GEVA)	N/A
GILD Gilead Sciences	0.27%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	538.36 million	534.27 million	Optionable
GEVA (GEVA)	N/A	N/A	N/A	Not Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.39 million	255.88 million	Optionable

GEVA, AMGN, GILD, and VRTX Headlines

Recent News About These Companies

E Fund Management Co. Ltd. Acquires 3,448 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 14 at 7:31 AM | marketbeat.com

S Bank Fund Management Ltd Invests $1.16 Million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 14 at 7:00 AM | marketbeat.com

Gulf International Bank UK Ltd Sells 4,524 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 14 at 6:51 AM | marketbeat.com

National Pension Service Grows Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 14 at 6:48 AM | marketbeat.com

LGT Group Foundation Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 14 at 6:16 AM | marketbeat.com

Prudential PLC Sells 5,451 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 14 at 6:06 AM | marketbeat.com

AGF Management Ltd. Raises Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 14 at 5:37 AM | marketbeat.com

The 5 Most Interesting Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

August 13 at 10:48 AM | finance.yahoo.com

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

August 13 at 10:01 AM | zacks.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Russell Investments Group Ltd.

August 13 at 7:03 AM | marketbeat.com

Resona Asset Management Co. Ltd. Purchases 4,535 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 13 at 6:54 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Callan Family Office LLC

August 13 at 6:37 AM | marketbeat.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Reaches New 52-Week Low - What's Next?

August 13 at 6:22 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Trillium Asset Management LLC

August 13 at 5:53 AM | marketbeat.com

Public Sector Pension Investment Board Grows Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 13 at 5:44 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Lowers Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 13 at 4:36 AM | marketbeat.com

Biotech Stocks To Add to Your Watchlist - August 11th

August 12 at 3:56 PM | marketbeat.com

Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

August 12 at 3:01 PM | seekingalpha.com

Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

August 12 at 2:34 PM | seekingalpha.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by AIA Group Ltd

August 12 at 7:44 AM | marketbeat.com

Motley Fool Wealth Management LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 12 at 6:47 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GEVA, AMGN, GILD, and VRTX Company Descriptions

Amgen NASDAQ:AMGN

$290.38 +1.05 (+0.36%)

Closing price 03:59 PM Eastern

Extended Trading

$289.00 -1.38 (-0.48%)

As of 04:10 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

(GEVA) NASDAQ:GEVA

Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company's other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.

Gilead Sciences NASDAQ:GILD

$119.04 -1.10 (-0.91%)

Closing price 03:59 PM Eastern

Extended Trading

$118.98 -0.06 (-0.05%)

As of 04:15 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Vertex Pharmaceuticals NASDAQ:VRTX

$390.96 -4.96 (-1.25%)

Closing price 03:59 PM Eastern

Extended Trading

$395.15 +4.19 (+1.07%)

As of 04:15 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time